What is CJC-1295 No DAC (Mod GRF 1-29)?

CJC-1295 no DAC, also known as Modified GRF (1-29), is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Developed in the 1980s, it mimics the first 29 amino acids of the 44-amino-acid GHRH protein, retaining its core functionality. This truncated form, similar to Sermorelin (GRF 1-29), is engineered for enhanced stability and receptor affinity.

Mod GRF (1-29) features four substituted amino acids to prevent degradation and oxidation during production, transport, and in vivo use. These modifications improve its binding to GHRH receptors, making it a valuable tool in peptide research. Its high bioavailability and minimal side effects, as demonstrated in mouse models, make it a promising candidate for various scientific studies.

• Structure: 29-amino-acid peptide with enhanced stability.
• Function: Stimulates growth hormone (GH) release via GHRH receptors.
• Administration: Typically studied via subcutaneous injection in preclinical models.

Cardiovascular Research Applications

Research on rodents suggests that Mod GRF (1-29) and similar GHRH analogs may support cardiac function post-myocardial infarction (heart attack). These compounds could improve heart health by:

• Enhancing cardiac repair and function.
• Reducing symptoms of heart failure.
• Offering potential therapeutic benefits for conditions like pulmonary hypertension and congenital heart defects.

Such findings highlight the peptide’s potential to increase longevity and improve quality of life in models of cardiovascular disease. Ongoing studies aim to explore its applications in human health, pending further clinical validation.

Related Research: Learn more about peptides in cardiovascular health.

Gastrointestinal System Benefits

Mod GRF (1-29) has shown promise in gastrointestinal research, particularly for conditions like inflammatory bowel disease (IBD), Crohn’s disease, and short bowel syndrome. While growth hormone (GH) therapy has been explored for these conditions, its long-term side effects limit its use. GHRH analogs like CJC-1295 no DAC offer a safer alternative.

Studies in primates indicate that Mod GRF (1-29) enhances bowel motility by interacting with vasoactive intestinal peptide (VIP) receptors and improving smooth muscle function. This is particularly relevant for:

• Treating constipation-related IBD.
• Supporting gastrointestinal and reproductive system health.
• Addressing unmet needs in chronic gastrointestinal disorders.

Explore More: Discover other peptides for gastrointestinal research.

Thyroid Function and Growth Hormone Connection

The interplay between thyroid function and growth hormone release is a critical area of peptide research. Studies involving individuals with hypothyroidism demonstrate that Mod GRF (1-29) elicits stronger GH responses when combined with thyroid replacement therapy. This suggests a synergistic relationship between thyroid hormones and GHRH analogs.

Mouse models further confirm the peptide’s efficacy, showing:

• High bioavailability through subcutaneous administration.
• Minimal side effects in preclinical settings.
• Potential to deepen understanding of human physiology.

These findings underscore the value of CJC-1295 no DAC in studying endocrine interactions and developing targeted therapies.

Learn More: Read about thyroid hormone research.

Why CJC-1295 No DAC is Valuable for Research

CJC-1295 no DAC (Mod GRF 1-29) is a versatile peptide for scientific exploration due to its:

• Stability: Modified structure resists degradation.
• Efficacy: Potent GHRH receptor activation.
• Applications: Spans cardiovascular, gastrointestinal, and endocrine research.
• Safety Profile: Minimal side effects in preclinical models.

Researchers continue to investigate its potential in addressing complex health challenges, from heart disease to digestive disorders and hormonal imbalances.

Conclusion

CJC-1295 no DAC (Mod GRF 1-29) is a powerful tool in peptide research, offering insights into cardiovascular repair, gastrointestinal motility, and thyroid-GH interactions. Its modified structure ensures stability and efficacy, making it a valuable asset for scientists studying human physiology and potential therapeutic applications.

For more information on CJC-1295 no DAC or to explore related peptides, contact our research team or browse our peptide research resources.

CTA: Stay updated on the latest peptide research. Subscribe to our newsletter for exclusive insights and study updates.